2024-03-29T10:13:57Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/52272022-10-14T13:08:41Zcom_20.500.12105_2152com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2153
00925njm 22002777a 4500
dc
Perez-Medina, Carlos
author
Abdel-Atti, Dalya
author
Tang, Jun
author
Zhao, Yiming
author
Fayad, Zahi A
author
Lewis, Jason S.
author
Mulder, Willem J M
author
Reiner, Thomas
author
2016
The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter (Zr-89-NRep) allows precise doxorubicin (DOX) quantification. Importantly, Zr-89-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. Zr-89-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with 425 mg kg(-1) DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy.
Nat Commun. 2016; 7:11838
2041-1723
http://hdl.handle.net/20.500.12105/5227
27319780
10.1038/ncomms11838
Nature Communications
PEGYLATED LIPOSOMAL DOXORUBICIN
METASTATIC BREAST-CANCER
NAB-PACLITAXEL
OVARIAN-CANCER
DRUG-DELIVERY
TUMOR
NANOMEDICINES
MANAGEMENT
ONCOLOGY
IMPACT
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy